Oncology

#Cancer research #Drug discovery #Events #Oncology #Webinar

Webinar: Latest developments in cancer research

This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More

Webinar date:
Sponsored by Scale Biosciences
#News

Theranostic radiopharmaceuticals
#Oncology #Radiochemistry #Radiopharmaceuticals

New standard ensures accurate dosing of radiopharmaceuticals

Scientists at the National Institute of Standards and Technology (NIST) have developed the first US standard for measuring the radioactivity of actinium-225, a radioactive isotope that drug companies are using to develop a new class of anticancer drugs.  The new standard, which is tied to the International… Read More

#Cancer Research #News

Neuroendocrine tumours
#ASCO #Clinical trial #Oncology #Perspective Therapeutics #Radiopharmaceuticals

Perspective shares positive responses in NETs at ASCO

Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.  The Phase I/IIa clinical trial is a multi-centre open-label dose escalation and dose expansion study of [212Pb]VMT-α-NET in patients with unresectable… Read More

#Cancer Research #News

Cancer cells
#Cancer research #Drug discovery #Events #Oncology #Webinar

Webinar: Cancer research developments

This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More

Webinar date:
Sponsored by Scale Biosciences
#News

Breast cancer
#ASCO #AstraZeneca #Breast cancer #Oncology #The Institute of Cancer Research

Camizestrant reduces risk of breast cancer progression by 56%

Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours.  The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research,… Read More

#Cancer Research #News #Trending News

Cancer tumour
#ASCO #Immunotherapy #Oncology #Rice University #Solid tumours #Spinout #Start-ups

Sentinel BioTherapeutics launches at 2025 ASCO Annual Meeting

Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting.   This is RBL's first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for its lead cancer… Read More

#Business & Investment #News #Start-up Zone

#Cancer research #Clinical trials #Oncology #OneOncology #Partnership #START Center for Cancer Research (START)

Strategic partnership to launch new clinical trial sites

The START Center for Cancer Research (START) and OneOncology has announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN, California), The Center for Cancer and Blood Disorders (CCBD, Texas), and Astera Cancer Care (New Jersey). This arrangement builds on… Read More

#Cancer Research #News

#Cancer research #Drug discovery #Events #Oncology #Webinar

Webinar: Innovation and development in cancer research

This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More

Webinar date:
Sponsored by Scale Biosciences
#News

Multiple myeloma
#GSK #Japan #Myeloma #Oncology

Blenrep combinations approved in Japan for multiple myeloma

Blenrep combinations have been approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma.  The approval follows an orphan drug designation for Blenrep in Japan, which was granted based on its ability to address high unmet need for patients… Read More

#News #Regulatory

#Colorectal cancer #Funding #Oncology #Start-ups #University of Arizona #University of Dundee

Start-up receives $4m towards ‘one-shot’ cancer drug

A drug discovery company co-founded by researchers at the University of Dundee and the University of Arizona has received $4 million in venture funding.  Branch Therapeutics, founded in November 2024, is a preclinical stage company seeking to develop drugs that are orally bioavailable, well-tolerated, and can treat multiple cancer types. … Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Liver cancer
#Moderna #mRNA #Oncology #Phase I trial #Solid tumours

Pan-tumour antigen therapy candidate enters the clinic

The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours.  The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik. Read More

#Cancer Research #News

#Cancer drug targets #Cancer research #Oncology #Proteins #Surfaceome

Shining a light on the surfaceome – the new frontier in cancer drug discovery

Reece Armstrong examines the advances being made in identifying cell surface proteins and what this means for cancer drug discovery. There have been some landmark FDA approvals in recent years – but not everyone has picked up on the significance of its decision to green-light Merus’ lung and pancreatic cancer… Read More

#Cancer Research #Exclusive Content

Great British Pounds, Investment
#BioNTech #Investment #Oncology #UK

BioNTech commits to up to £1 billion investment in the UK

Biopharmaceutical company BioNTech has announced a major investment of up to £1 ($1.3) billion over 10 years in the UK, potentially creating more than 400 new jobs in London and Cambridge.  The latest expansion of BioNTech’s presence in the UK builds on the company’s longstanding, positive strategic relationship and experience… Read More

#Business & Investment #News

Cancer research
#Cancer research #Drug discovery #Events #Oncology #Webinar

Webinar: Where are the developments in cancer research?

This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More

Webinar date:
Sponsored by Scale Biosciences
#News

#Clinical trials #Collaboration #Oncology

We need international partnerships to get new cancer drugs into the clinic

On International Clinical Trials Day, Lars Erwig, Director of the Centre for Drug Development at Cancer Research UK, calls for an international approach to clinical trials.  Launching a clinical trial for a new cancer treatment is a formidable challenge. For one thing, patient recruitment is arguably more difficult now than… Read More

#Cancer Research #Exclusive Content #Opinion

Cancer research in laboratory
#Investment #Oncology #Prostate cancer #University of Queensland

$1.25 million support for advanced prostate cancer drug

A $1.25 million investment is driving the development of a new treatment for advanced and therapy-resistant prostate cancer at The University of Queensland.  Based on research by Professor Greg Monteith from UQ’s School of Pharmacy and Pharmaceutical Sciences, the drug (QED-203) is being developed by the Queensland… Read More

#Cancer Research #Editor's Choice #News